Alexandros D. Tselepis

TL;DR: Oxidative stress appears to increase as CKD progresses and correlates significantly with level of renal function, and increased TAS seems to be dependent on several confounding variables, including increased uric acid levels, and therefore does not seem to be a reliable method for assessing the antioxidant capacity of patients with CKD.

TL;DR: The main structural and catalytic features of plasma PAF-AH are focused on, on the association of the enzyme with distinct lipoprotein particle subspecies, on its cellular sources, and finally on the potential significance of this lipop Protein-associated PLA(2) in cardiovascular disease.

TL;DR: ERA patients are characterized by an atherogenic lipid profile, which improves after therapy, and early immuno-intervention to control disease activity may reduce the risk of the atherosclerotic process and cardiovascular events in ERA patients.

TL;DR: The distribution, catalytic characteristics, and transfer of acetylhydrolase activity among plasma lipoprotein subspecies separated by isopycnic density gradient ultracentrifugation are examined and the possibility that the plasma enzyme may be partially derived from adherent monocytes has also been evaluated.

TL;DR: Physicians should consider using a PPARgamma agonist, such as pioglitazone, or statin use in those with NAFLD/NASH at high CVD or HCC risk, alone and/or preferably in combination with each other or with ezetimibe, for the primary or secondary prevention of CVD.